Camurus Stock

Camurus P/E 2024

Camurus P/E

94.71

Ticker

CAMX.ST

ISIN

SE0007692850

WKN

A2ABG7

As of Oct 6, 2024, Camurus's P/E ratio was 94.71, a 155.83% change from the 37.02 P/E ratio recorded in the previous year.

The Camurus P/E history

Camurus Aktienanalyse

What does Camurus do?

Camurus AB is a Swedish biopharmaceutical company that specializes in the development of innovative medications for the treatment of serious diseases. The company was founded in 1991 by an interdisciplinary team of chemists, biologists, and drug developers and is headquartered in Lund, Sweden. Camurus AB specializes in the development of medications based on long-acting drug release technology. This technology allows medications to be administered in a very precise manner and over a longer period of time. This enables the benefits of a constant drug concentration in the blood to be utilized without requiring multiple doses per day. The core business of Camurus AB includes the development of medications for the treatment of pain, cancer, and addiction. The company works closely with clients, partners, and academic institutions to bring innovative medications to market that can have a significant impact on patients' lives. One of Camurus AB's key areas is pain therapy. The company has developed a novel technology that allows pain medications to be administered in the form of sprays and patches. This technology is based on the release of buprenorphine, a potent painkiller that previously could only be administered as repeated single doses or in the form of an implant due to its short half-life. The extended release allows for a sustained high concentration of the drug in the blood, without the need for the patient to take multiple single doses. Camurus AB is also active in oncology and has developed medications for the treatment of breast and prostate cancer that also utilize long-acting drug release. These medications help patients better tolerate the side effects of chemotherapy and improve their quality of life. Another important area for Camurus AB is addiction therapy. The company has developed a medication based on buprenorphine for the treatment of opioid dependence. This medication activates the body's own opioid receptors and reduces the cravings for further drugs. In recent years, Camurus AB has introduced several important products to the market and holds a wide portfolio of patents and protective rights. The company is committed to improving patient care and making global healthcare a better and more effective system. In conclusion, Camurus AB is an innovative biopharmaceutical company specializing in the development of medications for the treatment of pain, cancer, and addiction. The company is dedicated to improving global healthcare and works closely with clients, partners, and academic institutions to develop innovative, effective, and patient-oriented solutions. Camurus ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Camurus's P/E Ratio

The Price to Earnings (P/E) Ratio of Camurus is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Camurus's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Camurus is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Camurus’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Camurus stock

What is the price-to-earnings ratio of Camurus?

The price-earnings ratio of Camurus is currently 94.71.

How has the price-earnings ratio of Camurus changed compared to last year?

The price-to-earnings ratio of Camurus has increased by 155.83% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Camurus high compared to other companies?

Yes, the price-to-earnings ratio of Camurus is high compared to other companies.

How does an increase in the price-earnings ratio of Camurus affect the company?

An increase in the price-earnings ratio of Camurus would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Camurus affect the company?

A decrease in the price-earnings ratio of Camurus would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Camurus?

Some factors that influence the price-earnings ratio of Camurus are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Camurus pay?

Over the past 12 months, Camurus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Camurus is expected to pay a dividend of 0 SEK.

What is the dividend yield of Camurus?

The current dividend yield of Camurus is .

When does Camurus pay dividends?

Camurus pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Camurus?

Camurus paid dividends every year for the past 0 years.

What is the dividend of Camurus?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Camurus located?

Camurus is assigned to the 'Health' sector.

Wann musste ich die Aktien von Camurus kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Camurus from 10/6/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Camurus pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Camurus in the year 2023?

In the year 2023, Camurus distributed 0 SEK as dividends.

In which currency does Camurus pay out the dividend?

The dividends of Camurus are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Camurus

Our stock analysis for Camurus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Camurus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.